Literature DB >> 33831250

A NSQIP-based randomized clinical trial evaluating choice of prophylactic antibiotics for pancreaticoduodenectomy.

Brian C Brajcich1,2, Clifford Y Ko1,3,4, Jason B Liu1,5, Ryan J Ellis1,2, Michael I D Angelica6.   

Abstract

Surgical site infection after pancreaticoduodenectomy is often caused by pathogens resistant to standard prophylactic antibiotics, suggesting that broad-spectrum antibiotics may be more effective prophylactic agents. This article describes the rationale and methodology underlying a multicenter randomized trial evaluating piperacillin-tazobactam compared with cefoxitin for surgical site infection prevention following pancreaticoduodenectomy. As the first US randomized surgical trial to utilize a clinical registry for data collection, this study serves as proof of concept for registry-based clinical trials.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  antibiotic prophylaxis; cefoxitin; clinical trial; pancreaticoduodenectomy; piperacillin; surgical wound infection; tazobactam drug combination

Mesh:

Substances:

Year:  2021        PMID: 33831250      PMCID: PMC8041048          DOI: 10.1002/jso.26402

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  46 in total

1.  Selection of prophylactic antibiotics according to the microorganisms isolated from surgical site infections (SSIs) in a previous series of surgeries reduces SSI incidence after pancreaticoduodenectomy.

Authors:  Kazuhiro Kondo; Kazuo Chijiiwa; Jiro Ohuchida; Masahiro Kai; Yoshiro Fujii; Kazuhiro Otani; Masahide Hiyoshi; Motoaki Nagano; Naoya Imamura
Journal:  J Hepatobiliary Pancreat Sci       Date:  2013-03       Impact factor: 7.027

2.  Preoperative biliary drainage does not increase major complications in pancreaticoduodenectomy: a large single center experience from the Massachusetts General Hospital.

Authors:  Klaus Sahora; Vicente Morales-Oyarvide; Cristina Ferrone; Zhi Ven Fong; Andrew L Warshaw; Keith D Lillemoe; Carlos Fernández-del Castillo
Journal:  J Hepatobiliary Pancreat Sci       Date:  2016-02-23       Impact factor: 7.027

Review 3.  Association of preoperative biliary drainage with postoperative outcome following pancreaticoduodenectomy.

Authors:  S P Povoski; M S Karpeh; K C Conlon; L H Blumgart; M F Brennan
Journal:  Ann Surg       Date:  1999-08       Impact factor: 12.969

4.  Novel Trial Designs: Lessons Learned from Thrombus Aspiration During ST-Segment Elevation Myocardial Infarction in Scandinavia (TASTE) Trial.

Authors:  Kristian Wachtell; Bo Lagerqvist; Göran K Olivecrona; Stefan K James; Ole Fröbert
Journal:  Curr Cardiol Rep       Date:  2016-01       Impact factor: 2.931

5.  Embedding a randomized clinical trial into an ongoing registry infrastructure: unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women).

Authors:  Connie N Hess; Sunil V Rao; David F Kong; Laura H Aberle; Kevin J Anstrom; C Michael Gibson; Ian C Gilchrist; Alice K Jacobs; Sanjit S Jolly; Roxana Mehran; John C Messenger; L Kristin Newby; Ron Waksman; Mitchell W Krucoff
Journal:  Am Heart J       Date:  2013-07-23       Impact factor: 4.749

6.  The Hawthorne Effect Revisited.

Authors:  Donald E Fry
Journal:  Dis Colon Rectum       Date:  2018-01       Impact factor: 4.585

7.  Clinicopathological parameters associated with surgical site infections in patients who underwent pancreatic resection.

Authors:  Atsushi Nanashima; Takafumi Abo; Junichi Arai; Shousaburo Oyama; Koji Mochinaga; Hirofumi Matsumoto; Katsunori Takagi; Masaki Kunizaki; Kazuo To; Hiroaki Takeshita; Shigekazu Hidaka; Takeshi Nagayasu
Journal:  Hepatogastroenterology       Date:  2014-09

8.  Preoperative biliary drainage: impact on intraoperative bile cultures and infectious morbidity and mortality after pancreaticoduodenectomy.

Authors:  S P Povoski; M S Karpeh; K C Conlon; L H Blumgart; M F Brennan
Journal:  J Gastrointest Surg       Date:  1999 Sep-Oct       Impact factor: 3.452

9.  ACS-NSQIP has the potential to create an HPB-NSQIP option.

Authors:  Henry A Pitt; Molly Kilbane; Steven M Strasberg; Timothy M Pawlik; Elijah Dixon; Nicholas J Zyromski; Thomas A Aloia; J Michael Henderson; Sean J Mulvihill
Journal:  HPB (Oxford)       Date:  2009-08       Impact factor: 3.647

10.  Incidence and risk factors for abdominal occult metastatic disease in patients with pancreatic adenocarcinoma.

Authors:  Georgios Gemenetzis; Vincent P Groot; Alex B Blair; Ding Ding; Sameer S Thakker; Elliot K Fishman; John L Cameron; Martin A Makary; Matthew J Weiss; Christopher L Wolfgang; Jin He
Journal:  J Surg Oncol       Date:  2018-10-31       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.